C-GB9JC2N Diagnostics
blood biomarkers, LC-MS/MS, Alzheimer’s diagnostics
diagnostics
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-GB9J
C-GB9JC-GB9Jblood biomarkers, LC-MS/MS, Alzheimer’s diagnostics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
C2N Diagnostics blood biomarkers, LC-MS/MS, Alzheimer’s diagnostics
C2N Diagnostics is a specialty diagnostics company providing laboratory services and products in brain health. Its high-resolution mass spectrometry-based biomarker products support clinical decision-making, clinical trials for neurodegeneration, and research into mechanisms of disease. Its Precivity blood tests are intended to help health care professionals assess amyloid plaques associated with Alzheimer’s disease in patients with cognitive impairment.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
C2N Diagnostics — Translational · Lower middle. Derived deterministically from 6 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic